Epigen was identified through amino acid sequence homology with other EGF family members. The sequence was initially obtained from mouse keratinocyte mRNA . Human Epigen cDNA encodes a 154 amino acid residue type I transmembrane precursor glycoprotein. This glycoprotein consists of a 22 amino acid signal peptide, an 88 amino acid extracellular domain, a 21 amino acid transmembrane domain, and a 23 amino acid cytoplasmic domain .
Epigen is expressed in normal human mammary tissue and in certain prostate and breast carcinomas . It binds to known EGF receptors, albeit with lower affinity compared to EGF. Despite this, Epigen is superior in inducing cell proliferation . It induces responses in MDA-MB-468 breast carcinoma cells and has effects on prostate cells and vascular endothelial cells . Epigen binds to ErbB1/Her1, causing receptor homodimerization and heterodimerization with other Erb/Her receptors .
Recombinant human Epigen (hEpigen) is produced in E. coli. The recombinant protein is typically purified to a high degree of purity, often greater than 98% as determined by SDS-PAGE . The bioactivity of recombinant hEpigen is measured in cell proliferation assays, with an ED50 typically between 2-30 ng/mL .
Recombinant Epigen is used in various research applications, particularly in studies related to cell proliferation and cancer research. It is important to note that products containing recombinant Epigen are labeled for research use only and are not approved for diagnostic or therapeutic purposes .
Epigen’s role in cell proliferation and its potential implications in cancer research make it a significant protein for further study and understanding.